FDA
-
-
-
-
-
-
-
Mesoblast names Facchina as new chair, Bell to stay as director
-
-
-
-
-
-
-
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
-
-
-
-
-
-
-
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
-
-
-
-
-
-
-
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
-
-
-
-
-
-
-
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
-
-
-
-
-
-
-
Mesoblast Limited (MESO) PT Raised to $15 at Piper Sandler as FDA Approves Ryoncil
-
-
-
-
-
-
-
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

